Net of competence of pediatric oncology, minimal residual disease in relapsed ALL

Net of competence of pediatric oncology, minimal residual disease in relapsed ALL
	The detection of minimal residual disease in childhood acute leukemia and Non-Hodgkin s lymphoma (NHL) might be an important tool for therapy stratification and monitoring of the response to therapy. Due to the progress of the detection methods several markers are known to be used for the identification of residual leukemic cells. The aim of this cooperative study is the evaluation of the most suitable marker for each type of disease. All results will be compared with clinical data provided by the therapy studies ALL-BFM (Schrappe, Hannover), AML-BFM (Creutzig/Ritter, Münster), ALL-REZ (Henze, Berlin), CoALL (Janka-Schaub, Hamburg), and ALL-NHL (Reiter, Gießen).
Head of Project:
	Charité - Universitätsmedizin Berlin Department of Pediatric Oncology and Hematology CVK
Begin/End of Project:
	10/1999 - 12/2002
Funded by:
	Sonstige
Scienceclassification:
	n.a.
Publications:
	(1) Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Pogoda M, Proba J, Henze G: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358:1239-41 (2001). (2.) Eckert C, Landt O, Taube T, Seeger K, Beyermann B, Proba J, Henze G: Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 14:316-23 (2000) (3.) Burmeister T, Maurer J, Aivado M, Elmaagacli AH, Grunebach F, Held KR, Hess G, Hochhaus A, Hoppner W, Lentes KU, Lubbert M, Schafer KL, Schafhausen P, Schmidt CA, Schuler F, Seeger K, Seelig R, Thiede C, Viehmann S, Weber C, Wilhelm S, Christmann A, Clement JH, Ebener U, Enczmann J, Leo R, Schleuning M, Schoch R, Thiel E: Quality assurance in RT-PCR-based BCR/ABL diagnostics - results of an interlaboratory test and a standardization approach. Leukemia 14:1850-6 (2001)